Advertisement

Topics

Latest "Gene Ontology Consortium" News Stories

05:26 EST 14th December 2018 | BioPortfolio

Here are the most relevant search results for "Gene Ontology Consortium" found in our extensive news archives from over 250 global news sources.

More Information about Gene Ontology Consortium on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Gene Ontology Consortium for you to read. Along with our medical data and news we also list Gene Ontology Consortium Clinical Trials, which are updated daily. BioPortfolio also has a large database of Gene Ontology Consortium Companies for you to search.

Showing "Gene Ontology Consortium" News Articles 1–25 of 4,900+

Friday 14th December 2018

FIT Biotech Oy: FIT Biotech's financial calendar and Annual General Meeting in 2019

FIT Biotech Oy Company release 14.12.2018 at 09:00 AM EET FIT Biotech's financial calendar and Annual General Meeting in 2019During the year 2019, FIT Biotech Oy will publish the Financial Statement release 2018 and Half Year Financial Report 2019 as follows: Financial Statement Release 2018: Thursday 28 February 2019  Half Year Financial Report 1-6/2019: Thursday 5 S...


Thursday 13th December 2018

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma

Bio-Rad Gene Pulser II Apparatus w/Pulse Controller Plus / Warranty

$149.95End Date: Saturday Jan-12-2019 16:17:31 PSTBuy It Now for only: $149.95Buy It Now | Add to watch list Biotech365 : Bio-Rad Gene Pulser II Apparatus w/Pulse Controller Plus / Warranty BioMarketplace You want to propose your products or a Biotech … Continue reading →


Excellent collection of #OpenAccess articles on gene therapy in @NatureOutlook https://www.nature.com/collections/cstccctvsh … #SickleCell https://www.nature.com/articles/d41586-018-07646-w … #Epilepsy https://www.nature.com/articles/d41586-018-

Excellent collection of #OpenAccess articles on gene therapy in @NatureOutlook https://www.nature.com/collections/cstccctvsh … #SickleCell https://www.nature.com/articles/d41586-018-07646-w … #Epilepsy

Genetic marker, predictor of early relapse in common childhood cancer discovered

Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.

Researchers seek to cure cancerous paediatric tumour

US researchers have come one step closer to helping children with cancer, recently authoring a study about paediatric cancer tumours called diffuse intrinsic pontine gliomas (DIPGs). Their multidisciplinary research, conducted by students at the University of Colorado Denver (CU Denver), focuses on identifying genetic mechanisms in order to develop therapeutic treatments for children with DIPGs. ...

Biogen pulls out of $1 billion partnership with AGTC after gene therapy trial failure

Shares of the Gainesville, Florida-based company plunged 38 percent when markets opened Thursday. Shares of other gene therapy companies were also down in Thursday trading.

Genetic marker, predictor of early relapse in pediatric ALL uncovered

Researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia (ALL) patients.

Orchard Therapeutics to Build New Gene Therapy Manufacturing Facility in California

NewsBuild-out is expected to begin in 2019 and ongoing plans call for adding more than100 full-time employees over the next few years.

AGTC Announces Topline Interim Six-Month Data from Phase 1/2 X-Linked Retinoschisis Clinical Study

Applied Genetic Technologies (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today reported topline interim six-month data from its Phase 1/2 clinical trial of rAAV2tYF-CB-hRS1, an investigational AAV-based gene therapy delivered via intravitreal injection for X-linked retinoschisis (XL...

Perspectum Diagnostics Announces Collaboration to Advance Development of Therapies for Patients with Serious Liver Disease

Creation of a major US-based network for sponsors focused on clinical development of drugs and diagnostics for patients with liver disease. Perspectum Diagnostics and the SC Liver Research Consortium (SCLRC) are delighted to announce a collaboration to advance clinical development of investigational therapies. This will focus on patients with seriou...

Biogen returns gene therapies to AGTC on lack of clinical activity

Orchard Therapeutics to Build Out Gene Therapy Manufacturing Site in Fremont, CA

Orchard Therapeutics said it will build out a gene therapy manufacturing facility in Fremont, CA, that will employ 100 people and expand its manufacturing capabilities to support plans for an expanded pipeline. The new facility, Orchard said, will enhance its capacity to develop and deliver lentiviral vector and gene-corrected hematopoetic stem cells for a wide […] The post Orchard Therapeut...

For Therapeutic Clowns, Silliness Is Serious Business

A quest to find out if therapeutic clowns were really helping disabled children who could not respond to their antics leads to an exploration of those kids' silent worlds. In other public health news: gene-editing, eczema and suicide, Zika, dirty air, tampons, salmonella, diabetes, and more.

Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

- ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with

$ORTX Announces the Build-out of New Gene Therapy Manufacturing Facility in California

$ORTX Announces the Build-out of New Gene Therapy Manufacturing Facility in California

Jeff Jonker Joins Ambys Medicines as President and CEO

-Company pursuing novel modalities including cell and gene therapies to regenerate the liver and restore liver function across multiple liver diseases- Ambys Medicines, a biotechnology company focused on discovering and developing regenerative and restorative therapies for people with advanced liver diseases, announced today that industry veteran Jeff ...

Early Career Profile: Dr Jasmina Cehajic Kapetanovic

Dr Jasmina Cehajic Kapetanovic is an NIHR Clinical Research Fellow and Fellow in vitreoretinal surgery, specialising in gene-therapy and robot-assisted retinal surgery. She works as an Oxford BRC-funded clinical scientist in the team of leading ophthalmology professor Robert MacLaren, the Oxford BRC’s Theme Lead for Surgical Innovation. Her research is focused on restoring vision and develo...

Viewpoint: Arguments against crop gene editing rely on ‘cherry-picking half-truths’

Viewpoint: FDA’s plan to regulate gene-edited animals as drugs is a ‘failed policy’

Foghorn® Therapeutics appoints Carl P. Decicco, Ph.D. as Chief Scientific Officer

Decicco also to become Venture Partner at Flagship Pioneering Foghorn® Therapeutics Inc. (Foghorn), a discoverer and developer of new medicines based on insights into genetic mutations in the chromatin regulatory system, and Flagship Pioneering, a unique life science innovation enterprise, today announced the appointment of Carl P. Decicco, Ph.D., as ...

U.S., Chinese academies planning meeting to set strict germline gene editing standards

Biogen scraps deal with AGTC to develop gene therapies for ophthalmic diseases https://www.firstwordpharma.com/node/1611290  $BIIB $AGTC

Biogen scraps deal with AGTC to develop gene therapies for ophthalmic diseases https://www.firstwordpharma.com/node/1611290  $BIIB $AGTC

Orchard to build gene therapy manufacturing plant in California

The planned investment comes months after Orchard struck a deal with GSK to take over development of the British pharma's gene therapy drugs.

New discovery will improve the safety and predictability of CRISPR

Scientists have discovered a simple set of rules that can be used to precisely predict how DNA will be modified by the CRISPR gene editing technique.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks